Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

• Status: Terminated
• Trial end date: 2016-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leo W. Jenkins Cancer Center
• Treatments: Famotidine; Interleukin-2

Criteria

Inclusion Criteria:

• Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment

• Total WBC recovery of 500 mm3 prior to IL-2 treatment

• Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment

• Active infection controlled prior to starting IL-2 treatment

• Stable systolic blood pressure > 90mm Hg prior to starting IL-2 treatment

• O2 saturation >90% prior to starting treatment

• Stable cardiopulmonary status prior to starting IL-2 treatment

• Serum creatinine < or equal to 2.0 mg/dl

• Total bilirubin and AST <3x upper limits normal

Exclusion Criteria:

• Acute Promyelocytic Leukemia

• Active thrombocytopenic bleeding

• Cardiac ejection fraction below 45%

• Pregnancy and/or lactation